Arcotatug Tavatecan

**Semantic type:** Pharmacologic Substance

**Definition:** An antibody-drug conjugate (ADC) composed of arcotatug, a Fc-silenced humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against the tumor-associated antigen (TAA) Claudin18.2 (CLDN18.2; A2 isoform of claudin-18), conjugated, via a cleavable linker, to the cytotoxic agent and DNA topoisomerase I inhibitor exatecan, with potential antineoplastic activity. Upon administration, arcotatug tavatecan specifically targets and binds to CLDN18.2 expressed on tumor cells. Upon internalization and linker cleavage within the tumor cell, exatecan is released and inhibits DNA topoisomerase I activity, thereby inhibiting DNA replication and resulting in DNA damage, cell cycle arrest and apoptosis in tumor cells overexpressing CLDN18.2. CLDN18.2, a tight junction protein and stomach-specific isoform of claudin-18, is expressed on a variety of tumor cells. Its expression in healthy tissues is strictly confined to short-lived differentiated epithelial cells of the gastric mucosa.

**Synonyms:** - ADC IBI343 - ARCOTATUG TAVATECAN - Anti-CLDN18.2 ADC IBI343 - Anti-CLDN18.2/Exatecan Antibody-drug Conjugate IBI343 - Anti-Claudin18.2 Antibody-drug Conjugate IBI343 - Anti-Claudin18.2/Exatecan Antibody-drug Conjugate IBI343 - IBI 343 - IBI-343 - IBI343